AstraZeneca’s Andexxa May Continue Dangling In Accelerated Approval After Mixed Advisory Panel

The Cellular, Tissue and Gene Therapies Advisory Committee appeared unsatisfied with the risk-benefit balance of the anticoagulant reversal agent in the confirmatory trial, but was not ready to throw out the product, suggesting new trials may be needed.